Redeye lowers its short-term Enea estimates on the back of a weaker Q1 than expected. We believe the Q1 sales drop (-8%) is a good example of the quarterly fluctuation for periods with no new, major deals. Seen in that light, Q1 was stable, especially considering the challenging comps. We maintain our positive view and our valuation.